Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

類似資料

• Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models
  著者:: Sun, Jessica D, 等
  出版事項: (2015)
• Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
  著者:: Sun, Jessica D, 等
  出版事項: (2015)
• Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models
  著者:: Sun, Jessica D., 等
  出版事項: (2016)
• Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()
  著者:: Kumar, Sushil, 等
  出版事項: (2018)
• TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
  著者:: Liu, Qian, 等
  出版事項: (2012)